WCN26-9116 EFFICACY OF PEGCETACOPLAN IN PATIENTS WITH LOWER BASELINE PROTEINURIA: A SUBGROUP ANALYSIS FROM THE VALIANT TRIAL

20260 citationsJournal Articlegold Open Access

Authors

Seung Hyeok Han · Yonsei University

H J Kang · Seoul National University Children's Hospital

Nicholas Webb · Swedish Orphan Biovitrum (Sweden)

Johan Szamosi · Swedish Orphan Biovitrum (Sweden)

Regina Horneff · Swedish Orphan Biovitrum (Sweden)

K. Gordon · Apellis Pharmaceuticals (United States)

Yiwei Zhang

Abstract

Conclusion: Clinical efficacy of 52 weeks of pegcetacoplan treatment for adolescents was consistent with the overall population of VALIANT, confirming its sustained benefit in broad patient populations.

Topics & Keywords

Antiplatelet Therapy and Cardiovascular Diseases Inflammatory Bowel Disease Peripheral Artery Disease Management

UN Sustainable Development Goals

Zero hunger

Publication Details

Published in: Kidney International Reports

Volume 11, Issue 4, pp. 106328-106328

DOI: 10.1016/j.ekir.2026.106328

Field-Weighted Citation Impact: 0.00